StocksMedium•5 November 2026•
1 min read
Eli Lilly Halts Alzheimer’s Drug Development Following Phase 2 Failure
Key Facts
1Eli Lilly has discontinued its Alzheimer’s disease drug candidate following results from a phase 2 clinical trial.
Eli Lilly has discontinued the development of an experimental Alzheimer’s disease drug candidate following results from a phase 2 clinical trial. MedWatch reported that the decision was driven by clinical data indicating the candidate failed to meet necessary benchmarks during the second phase of testing.
LLY closed at $1417.99 on November 4, 2026, with the stock reaching a day high of $1445.96 and a low of $1401.59. This negative R&D outcome occurs despite the company maintaining a broad therapeutic pipeline and existing approved treatments for Alzheimer's disease.